Advanced search
Publication Cover
Acta Oncologica Volume 58, 2019 - Issue 1
Journal homepage
4,305
Views
48
CrossRef citations to date
0
Altmetric
LETTERS TO THE EDITOR: MEDICAL ONCOLOGY

Pazopanib in relapsed osteosarcoma patients: report on 15 cases

Alessandra LonghiDepartment of Chemotherapy, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy; Correspondence[email protected]
,
Anna PaioliDepartment of Chemotherapy, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy;
,
Emanuela PalmeriniDepartment of Chemotherapy, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy; ORCID Iconhttp://orcid.org/0000-0003-3406-6705
ORCID Icon,
Marilena CesariDepartment of Chemotherapy, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy;
,
Massimo E. AbateDepartment of Chemotherapy, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy;
,
Elisabetta SetolaDepartment of Chemotherapy, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy;
,
Paolo SpinnatoDepartment of Radiology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy;
,
Davide DonatiOrthopedic Surgery, Orthopedic Oncologic Surgery, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy;
,
Ivar HomplandDepartment of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway
&
Kjetil BoyeDepartment of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway
 show all
Pages 124-128 | Published online: 12 Sep 2018

Citations (48)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Cristina Meazza & Sebastian Dorin Asaftei. (2021) State-of-the-art, approved therapeutics for the pharmacological management of osteosarcoma. Expert Opinion on Pharmacotherapy 22:15, pages 1995-2006.
Read now
Cristina Meazza, Roberto Luksch & Alessandro Luzzati. (2021) Managing axial bone sarcomas in childhood. Expert Review of Anticancer Therapy 21:7, pages 747-764.
Read now
Feifei Sun, Suying Lu, Zijun Zhen, Jia Zhu, Juan Wang, Junting Huang, Yu Zhang, Hui Li, Ruiqing Cai, Meiling Liu, Liuhong Wu, Xiaofei Sun & Yizhuo Zhang. (2020) The Efficacy and Safety of Apatinib in Refractory/Relapse Advanced Pediatric Solid Tumor: A Retrospective Study. Cancer Management and Research 12, pages 6177-6185.
Read now
Cristina Meazza, Stefano Bastoni & Paolo Scanagatta. (2020) What is the best clinical approach to recurrent/refractory osteosarcoma?. Expert Review of Anticancer Therapy 20:5, pages 415-428.
Read now

Articles from other publishers (44)

Riley M. Goldsmith, Jessica L. Xing, Cory W. Heal, Michelina C. De La Maza & Baldassarre Stea. (2024) Stereotactic Body Radiation Therapy and Concurrent Targeted Therapy for Lung Metastases in Pediatric Sarcoma. Advances in Radiation Oncology 9:7, pages 101517.
Crossref
Ksenia Menshikh, Ivana BanicevicBojana ObradovicLia Rimondini. (2024) Biomechanical Aspects in Bone Tumor Engineering. Tissue Engineering Part B: Reviews 30:2, pages 217-229.
Crossref
Ahmad Assi, Mohamad Farhat, Maria Catherine Rita Hachem, Ziad Zalaquett, Marven Aoun, Mohammad Daher, Amer Sebaaly & Hampig-Raphaël Kourie. (2023) Tyrosine kinase inhibitors in osteosarcoma: Adapting treatment strategiesa. Journal of Bone Oncology 43, pages 100511.
Crossref
Mohamed A. Gouda, Maria A. Zarzour, Ara A. Vaporciyan, Kalevi Kairemo, Hubert H. Chuang & Vivek Subbiah. (2023) Activity of pazopanib in EWSR1-NFATC2 translocation-associated bone sarcoma. Oncoscience 10, pages 44-53.
Crossref
Katsutsugu Umeda, Akio Sakamoto, Takashi Noguchi, Yoshinori Uchihara, Hirokazu Kobushi, Ryo Akazawa, Hideto Ogata, Satoshi Saida, Itaru Kato, Hidefumi Hiramatsu, Megumi Uto, Takashi Mizowaki, Hironori Haga, Hiroshi Date, Takeshi Okamoto, Kenichiro Watanabe, Souichi Adachi, Junya Toguchida, Shuichi Matsuda & Junko Takita. (2023) Clinical Outcomes of Patients With Osteosarcoma Experiencing Relapse or Progression: A Single-institute Experience. Journal of Pediatric Hematology/Oncology 45:3, pages e356-e362.
Crossref
Emmy D. G. Fleuren, Myrella Vlenterie & Winette T. A. van der Graaf. (2023) Recent advances on anti-angiogenic multi-receptor tyrosine kinase inhibitors in osteosarcoma and Ewing sarcoma. Frontiers in Oncology 13.
Crossref
Gabriel J David Tarud, Luisa Fernanda Atunes Ortega, Katiuska R Molina Pacheco & Tufith A Atunes Celedón. (2023) Osteosarcoma multicéntrico sincrónico en paciente pediátrico de 15 años. Reporte de un caso. Pediatría 55:4, pages 215-221.
Crossref
Laxmikant Gautam, Monika Vishwakarma, Indu Lata Kanwar, Priya Shrivastava & Suresh P. Vyas. 2023. Synbiotics for the Management of Cancer. Synbiotics for the Management of Cancer 1 40 .
Víctor Albarrán, María Luisa Villamayor, Jesús Chamorro, Diana Isabel Rosero, Javier Pozas, María San Román, Juan Carlos Calvo, Patricia Pérez de Aguado, Jaime Moreno, Patricia Guerrero, Carlos González, Coral García de Quevedo, Pablo Álvarez-Ballesteros & María Ángeles Vaz. (2022) Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas. International Journal of Molecular Sciences 23:22, pages 13784.
Crossref
Yinda Qiu, Hao Yan, Ruiling Zheng, Xiaojing Chen, Yi Wang, Qi Yan, Yanfei Ye, Jianxia Zhang, Haoyi Han, Kun Wang, Yunjie Zhao, Lehao Huang, Xiaokun Li & Zhiguo Liu. (2022) cyy260 suppresses the proliferation, migration and tumor growth of osteosarcoma by targeting PDGFR-β signaling pathway. Chemico-Biological Interactions 367, pages 110200.
Crossref
Meng Cai, Jie Zhu & Guangxin Zhou. (2022) Efficacy and Safety of Treating Refractory Bone and Soft Tissue Sarcoma with Anlotinib in Different Treatment Patterns. Computational and Mathematical Methods in Medicine 2022, pages 1-10.
Crossref
Mubashir Hassan, Muhammad Yasir, Saba Shahzadi & Andrzej Kloczkowski. (2022) Exploration of Potential Ewing Sarcoma Drugs from FDA-Approved Pharmaceuticals through Computational Drug Repositioning, Pharmacogenomics, Molecular Docking, and MD Simulation Studies. ACS Omega 7:23, pages 19243-19260.
Crossref
Joaquim Soares do Brito, Miguel Esperança-Martins, André Abrunhosa-Branquinho, Cecilia Melo-Alvim, Raquel Lopes-Brás, João Janeiro, Dolores Lopez-Presa, Isabel Fernandes, José Portela & Luis Costa. (2022) Management of Unresectable Localized Pelvic Bone Sarcomas: Current Practice and Future Perspectives. Cancers 14:10, pages 2546.
Crossref
Xiaojing Chen, Lu Liu, Peng Liu, Yingying Chen, Dan Lin, Hao Yan, Qi Yan, Yi Wang, Yinda Qiu, Bo Fang, Huijing Huang, Jianchang Qian, Yunjie Zhao, Zhou Du, Qianwen Zhang, Xiaokun Li, Xiaohui Zheng & Zhiguo Liu. (2022) Discovery of Potent and Orally Bioavailable Platelet-Derived Growth Factor Receptor (PDGFR) Inhibitors for the Treatment of Osteosarcoma. Journal of Medicinal Chemistry 65:7, pages 5374-5391.
Crossref
Christopher E. Lietz, Erik T. Newman, Andrew D. Kelly, David H. Xiang, Ziying Zhang, Caroline A. Luscko, Santiago A. Lozano-Calderon, David H. Ebb, Kevin A. Raskin, Gregory M. Cote, Edwin Choy, G. Petur Nielsen, Benjamin Haibe-Kains, Martin J. Aryee & Dimitrios Spentzos. (2022) Genome-wide DNA methylation patterns reveal clinically relevant predictive and prognostic subtypes in human osteosarcoma. Communications Biology 5:1.
Crossref
G.M. Guimarães, F. Tesser-Gamba, A.S. Petrilli, C.R.P. Donato-Macedo, M.T.S. Alves, F.T. de Lima, R.J. Garcia-Filho, R. Oliveira & S.R.C. Toledo. (2021) Molecular profiling of osteosarcoma in children and adolescents from different age groups using a next-generation sequencing panel. Cancer Genetics 258-259, pages 85-92.
Crossref
Zhiyong Liu, Songtao Gao, Liangyu Zhu, Jiaqiang Wang, Peng Zhang, Po Li, Fan Zhang & Weitao Yao. (2021) Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study. Cancer Medicine 10:21, pages 7593-7600.
Crossref
Yun Liu, Nenggan Huang, Shijie Liao, Emel Rothzerg, Felix Yao, Yihe Li, David Wood & Jiake Xu. (2021) Current research progress in targeted anti‐angiogenesis therapy for osteosarcoma. Cell Proliferation 54:9.
Crossref
Oskar Steinbrecher, Thomas Brodowicz & Wolfgang Lamm. (2021) Novel agents in a young patient with osteosarcoma: A short review. memo - Magazine of European Medical Oncology 14:3, pages 304-308.
Crossref
Kjetil Boye, Alessandra Longhi, Tormod Guren, Susanne Lorenz, Stine Næss, Michela Pierini, Ingeborg Taksdal, Ingvild Lobmaier, Marilena Cesari, Anna Paioli, Ayca M. Løndalen, Elisabetta Setola, Ivar Hompland, Leonardo A. Meza-Zepeda, Kirsten Sundby Hall & Emanuela Palmerini. (2021) Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial. Cancer Immunology, Immunotherapy 70:9, pages 2617-2624.
Crossref
Marissa A. Just, David Van Mater & Lars M. Wagner. (2021) Receptor tyrosine kinase inhibitors for the treatment of osteosarcoma and Ewing sarcoma. Pediatric Blood & Cancer 68:8.
Crossref
Rebekah Belayneh, Mitchell S. Fourman, Sumail Bhogal & Kurt R. Weiss. (2021) Update on Osteosarcoma. Current Oncology Reports 23:6.
Crossref
Tarek Assi, Sarah Watson, Bachar Samra, Elie Rassy, Axel Le Cesne, Antoine Italiano & Olivier Mir. (2021) Targeting the VEGF Pathway in Osteosarcoma. Cells 10:5, pages 1240.
Crossref
Hiromichi Oshiro, Yasunori Tome, Kentaro Miyake, Takashi Higuchi, Norihiko Sugisawa, Fuminori Kanaya, Kotaro Nishida & Robert M. Hoffman. (2021) An mTOR and VEGFR inhibitor combination arrests a doxorubicin resistant lung metastatic osteosarcoma in a PDOX mouse model. Scientific Reports 11:1.
Crossref
Zhichao Tian, Huimin Liu, Yao Zhao, Xiaofeng Wang, Hongyan Ren, Fan Zhang, Po Li, Peng Zhang, Jiaqiang Wang & Weitao Yao. (2020) Secondary pneumothorax as a potential marker of apatinib efficacy in osteosarcoma: a multicenter analysis. Anti-Cancer Drugs 32:1, pages 82-87.
Crossref
Fiorela N. Hernandez Tejada, Alejandro Zamudio, Mario L. Marques-Piubelli, Branko Cuglievan & Douglas Harrison. (2020) Advances in the Management of Pediatric Sarcomas. Current Oncology Reports 23:1.
Crossref
Audrey Perret, Julien Dômont, Ali N. Chamseddine, Sarah N. Dumont, Benjamin Verret, Sylvain Briand, Charles Court, Thierry Lazure, Julien Adam, Carine Ngo, Caroline Even, Antonin Levy, Arnaud Bayle, Francesca Lucibello, Leila Haddag‐Miliani, Matthieu Faron, Charles Honoré, Axel Le Cesne & Olivier Mir. (2020) Efficacy and safety of oral metronomic etoposide in adult patients with metastatic osteosarcoma. Cancer Medicine 10:1, pages 230-236.
Crossref
Alejandro Cabrera-Andrade, Andrés López-Cortés, Gabriela Jaramillo-Koupermann, Humberto González-Díaz, Alejandro Pazos, Cristian R. Munteanu, Yunierkis Pérez-Castillo & Eduardo Tejera. (2020) A Multi-Objective Approach for Anti-Osteosarcoma Cancer Agents Discovery through Drug Repurposing. Pharmaceuticals 13:11, pages 409.
Crossref
Maria Anna Smolle, Joanna Szkandera, Dimosthenis Andreou, Emanuela Palmerini, Marko Bergovec & Andreas Leithner. (2020) Treatment options in unresectable soft tissue and bone sarcoma of the extremities and pelvis – a systematic literature review. EFORT Open Reviews 5:11, pages 799-814.
Crossref
Emanuela Palmerini, Alberto Righi & Eric L. Staals. (2020) Rare Primary Malignant Bone Sarcomas. Cancers 12:11, pages 3092.
Crossref
Anita K. Luu & Alicia M. Viloria-Petit. (2020) Targeting Mechanotransduction in Osteosarcoma: A Comparative Oncology Perspective. International Journal of Molecular Sciences 21:20, pages 7595.
Crossref
Shinji Tsukamoto, Costantino Errani, Andrea Angelini & Andreas F. Mavrogenis. (2020) Current Treatment Considerations for Osteosarcoma Metastatic at Presentation. Orthopedics 43:5.
Crossref
Zhichao Tian, Xiaohui Niu & Weitao Yao. (2020) Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?. Frontiers in Oncology 10.
Crossref
Ryo Akazawa, Katsutsugu Umeda, Satoshi Saida, Itaru Kato, Hidefumi Hiramatsu, Akio Sakamoto, Yoshiki Arakawa, Shinji Sumiyoshi, Takeshi Okamoto, Hiroshi Moritake, Souichi Adachi & Junko Takita. (2020) Temozolomide and etoposide combination for the treatment of relapsed osteosarcoma. Japanese Journal of Clinical Oncology 50:8, pages 948-952.
Crossref
Florence Duffaud. (2020) Role of TKI for Metastatic Osteogenic Sarcoma. Current Treatment Options in Oncology 21:8.
Crossref
Anna M. Czarnecka, Kamil Synoradzki, Wiktoria Firlej, Ewa Bartnik, Pawel Sobczuk, Michal Fiedorowicz, Pawel Grieb & Piotr Rutkowski. (2020) Molecular Biology of Osteosarcoma. Cancers 12:8, pages 2130.
Crossref
Isabelle Corre, Franck Verrecchia, Vincent Crenn, Francoise Redini & Valérie Trichet. (2020) The Osteosarcoma Microenvironment: A Complex but Targetable Ecosystem. Cells 9:4, pages 976.
Crossref
Jie Zhao, Dylan C. Dean, Francis J. Hornicek, Xiuchun Yu & Zhenfeng Duan. (2020) Emerging next-generation sequencing-based discoveries for targeted osteosarcoma therapy. Cancer Letters 474, pages 158-167.
Crossref
Ninna Aggerholm-Pedersen, Phillip Rossen, Hanne Rose & Akmal Safwat. (2020) Pazopanib in the Treatment of Bone Sarcomas: Clinical Experience. Translational Oncology 13:2, pages 295-299.
Crossref
Edward M. Greenfield, Christopher D. Collier & Patrick J. Getty. 2020. Current Advances in the Science of Osteosarcoma. Current Advances in the Science of Osteosarcoma 141 155 .
Cinzia Zucchini, Maria Cristina Manara, Camilla Cristalli, Marianna Carrabotta, Sara Greco, Rosa Simona Pinca, Cristina Ferrari, Lorena Landuzzi, Michela Pasello, Pier-Luigi Lollini, Marco Gambarotti, Davide Maria Donati & Katia Scotlandi. (2019) ROCK2 deprivation leads to the inhibition of tumor growth and metastatic potential in osteosarcoma cells through the modulation of YAP activity. Journal of Experimental & Clinical Cancer Research 38:1.
Crossref
Yoshiyuki Suehara, Deepu Alex, Anita Bowman, Sumit Middha, Ahmet Zehir, Debyani Chakravarty, Lu Wang, George Jour, Khedoudja Nafa, Takuo Hayashi, Achim A. Jungbluth, Denise Frosina, Emily Slotkin, Neerav Shukla, Paul Meyers, John H. Healey, Meera Hameed & Marc Ladanyi. (2019) Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations. Clinical Cancer Research 25:21, pages 6346-6356.
Crossref
. (2019) Pazopanib. Reactions Weekly 1747:1, pages 226-226.
Crossref
Tiffany Seto, Mee-Na Song, Maily Trieu, Jeanette Yu, Manpreet Sidhu, Chi-Mei Liu, Danny Sam & Minggui Pan. (2019) Real-World Experiences with Pazopanib in Patients with Advanced Soft Tissue and Bone Sarcoma in Northern California. Medical Sciences 7:3, pages 48.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.